• Home
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Journal PharmaceuticalIntelligence.com
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2022 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • SOP Web STAT
  • Blockchain Transactions Network Ecosystem
  • Contact Us
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Feeds:
Posts
Comments

Portfolio of IP Assets

New Concepts for Valuation of Portfolios of Intellectual Property Asset Classes: LPBI Group – A Case in Point

Author and Curator of own ideas and contents: Aviva Lev-Ari, PhD, RN, Founder of 1.0 LPBI and of 2.0 LPBI Group

I acknowledge inputs to this article from:

Erich Greenbaum, the references to DAO and IP-NFT

Dr. Ofer Markman, comments on the Table

Prof. Stephen J. Williams, comments on the Table and on the applicability of IP-NFT concept to LPBI Group’s Portfolio of IP.

 

Updated on 2/25/2022

We equate a major portion of LPBI Group’s Portfolio of  Intellectual Properties to be #SNFT aka, SCIENTIFIC NON FUNGIBLE TOKENS

We define smart contracts for dissemination of #SNFT as

the #liquidity of Scientific #knowledge


LPBI Group’s Portfolio of IP Assets as #SNFT include:

 

IP Asset Class I (+6K #SNFT)

  • All the article curations in LPBI Group’s +6,100 scientific #articles in PharmaceuticalIntelligence.com


IP Asset Class II

  • All electronic Table of Contents (eTOCs) of 18 Books in Medicine, aka BioMed e-Series

https://lnkd.in/ekWGNqA

  • All eTOCs in Spanish Audio
  • All eTOCs in Bi-Lingual English-Spanish Text
  • All eTOCs in English Text

 

  • All Cover Pages of 18 Books in Medicine – English Edition

IP Asset Class XII using inputs from IP Asset Class II

  • All Cover Pages of 18 Books in Medicine – Spanish Translation by Series:

Series A: Cardiovascular – 6 volumes
Series B: Genomics – 2 volumes
Series C: Cancer – 2 volumes
Series D: Immunology – 4 volumes
Series E: Precision Medicine

  • All Editorials of 18 Books – English Text
  • All Editorials of 18 Books – English Audio


IP Asset Class V (+6K #SNFT)

  • All Biological Images in Books, 18 volumes
  • All Legends of images in Text format – considered for Text Analysis with Machine learning
  • Gallery of Biological Images +6200
  • Biological Images in Journal articles https://lnkd.in/eteNqpF not in Books

IP Asset Class XII – Part B of New Genre of Scientific Books

  • Text Analysis with AI, Machine Learning – Natural Language Processing (NLP) Statistical & Deep Learning (DL) on

– Two books in Genomics
– Two books in Cancer & Oncology

  • Graphic results of NLP and DL:

– Hypergraph Plots, one graph per Chapter and Expert interpretation text
– Tree Diagram Plots, one graph per Chapter and Expert interpretation text

 

IP Asset Class III

• 100 e-Proceedings of Biotech conferences

• 40 Tweet Collections of 40 of the 100 conferences

#oncology #biotech #medicine #ai #deeplearning #machinelearning #nlp #genomics #translation #graphic #hypergraph #cardiovascular #immunology #precisionmedicine #cancer #intellectualproperty

 

2.0 LPBI Missions

Four missions as LPBI’s exposition of the pipelines for 2021 -2025:

Mission #1:  NLP – Team in USA & India – Medical Text Analysis with NLP – on LPBI 3.3 Giga Bytes of Content. Statistical NLP and Deep Learning by Machine Learning using Wolfram Language for Biological Sciences

https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/

Mission #2:  Blockchain IT and NLP Processing API generating NLP visualization Products used by Knowledge Graphs stored in Graph Databases – Content monetization infrastructure B2B and B2C.

https://pharmaceuticalintelligence.com/blockchain-transactions-network/

Mission #3:  BioMed e-Books – Book Republishing in new GENRE – Bi-Lingual and Multimedia Audio Podcast for Books in the 18-e-Books in five e-Series: A,B,C,D,E

https://pharmaceuticalintelligence.com/2021/07/24/proposal-for-new-e-book-architecture-combining-a-bi-lingual-etocs-english-spanish-with-nlps-results-of-medical-text-analysis-series-b-genomics-volume-1-2-and-series-c-cancer-volume-1/

Mission #4:  Synthetic Biology Software: Drug discovery Galectins

https://pharmaceuticalintelligence.com/synthetic-biology-in-drug-discovery/

2.0 LPBI is a Very Unique Organization 

Author: Aviva Lev-Ari, PhD, RN, Founder of 1.0 LPBI and 2.0 LPBI, April 2012 to Present

https://pharmaceuticalintelligence.com/2021/03/02/2-0-lpbi-is-a-very-unique-organization/

LPBI Group’s Portfolio of 14 Intellectual Property Asset Classes

Two New Concepts in Valuation of IP Asset Classes: DAO and IP-NFT

Please review these two articles before reviewing the Table, below

What is a decentralized autonomous organization, and how does a DAO work?

https://cointelegraph.com/ethereum-for-beginners/what-is-a-decentralized-autonomous-organization-and-how-does-a-dao-work

 

IP-NFTs for Researchers: A New Biomedical Funding Paradigm

https://medium.com/molecule-blog/ip-nfts-for-researchers-a-new-biomedical-funding-paradigm-91312d8d92e6

https://medium.com/molecule-blog/ip-nfts-for-researchers-a-new-biomedical-funding-paradigm-91312d8d92e6

How do we see applicability of NFT to LPBI Group’s Intellectual Property Portfolio?

Data in tables updated on November 14, 2021

Data represent the views of LPBI Group’s Founder

For a detailed description of 1.0 LPBI Portfolio of IP Assets please review

1.0 LPBI 2012-2020 VISTA

https://pharmaceuticalintelligence.com/2019-vista/

For a detailed description of 2.0 LPBI Portfolio of IP Assets please review

2.0 LPBI 2021-2025 VISION

https://pharmaceuticalintelligence.com/vision/

In the Voice of Dr. Williams

See the columns under Dr. Williams Name

 

The reasoning will be discussed below but first the reader is directed to the two links: one a video and the second a blog on NFT Assets and Business Exits

Please View Video

https://www.youtube.com/embed/LU5Mv4TQEE8

The whole point of NFT is that the word “fungible” can also mean replacable so a non fungible asset cannot be replaced or even reproduced. Think of the Mona Lisa. It can be reproduced but not by the original artist so there is only one first nonfungible Mona Lisa.

This NFT concept works well in the art world but for assets you want to reproduce and sell over and over this concept is very poor and would not work well at all. It is a tempting idea for assests which may not have an ideal way to sell however most of LPBI assest are in fact, fungible.

 

Other related articles on this Open Access Online Scientific Journal to this topic include the following:

Data Architecture for Blockchain Deployment of Digital Assets: LPBI IP Asset Classes I,II,III,V

Author: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2020/11/16/data-architecture-for-blockchain-deployment-of-digital-assets-lpbi-ip-asset-classes-iiiiii/

February 1, 2021 – We Celebrate 1,924,400 e-Readers, 6,000 Scientific Journal Articles, 7,525 Scientific Comments, A Journal Ontology of 728 Medical & Life Sciences Research Categories, 10,440 Tags, Top Article 17,300 Views, Top Author 487,500 Views on PharmaceuticalIntelligence.com

Reporter: Aviva Lev-Ari, PhD, RN

Update on 7/1/2021 by Srinivas Sriram and Abhisar Anand

https://pharmaceuticalintelligence.com/2021/02/01/february-1-2021-we-celebrate-1924400-e-readers-6000-scientific-journal-articles-7525-scientific-comments-a-journal-ontology-of-728-medical-life-sciences-research-categories-10440-tag/

The Map of human proteins drawn by artificial intelligence and PROTAC (proteolysis targeting chimeras) Technology for Drug Discovery

Curators: Dr. Stephen J. Williams and Aviva Lev-Ari, PhD, RN

UPDATED on 11/5/2021

https://pharmaceuticalintelligence.com/2021/10/21/the-map-of-human-proteins-drawn-by-artificial-intelligence-and-protac-proteolysis-targeting-chimeras-technology-for-drug-discovery/

WORKFLOW for a Ten-Steps Medical Text Analysis Operation using NLP on LPBI Medical and Life Sciences Content

Author: Aviva Lev-Ari, PhD, RN with inputs related to Wolfram NLP Code by Madison Davis and Yash Choudhary

https://pharmaceuticalintelligence.com/2021/07/15/workflow-for-a-ten-steps-medical-text-analysis-operation-using-nlp-on-lpbi-medical-and-life-sciences-content/

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to print (Opens in new window)
  • Click to email a link to a friend (Opens in new window)

Like this:

Like Loading...

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 1,254 other subscribers
  • Recent Posts

    • Press Release for Five Bilingual BioMed e-Series January 29, 2023
    • 2022 FDA Drug Approval List, 2022 Biological Approvals and Approved Cellular and Gene Therapy Products January 17, 2023
    • Verily announced other organizational changes, 1/13/2023 January 16, 2023
    • Mission 4: Use of Systems Biology for Design of inhibitor of Galectins as Cancer Therapeutic – Strategy and Software December 13, 2022
    • Science Has A Systemic Problem, Not an Innovation Problem December 12, 2022
    • Chemistry Nobelist Carolyn Bertozzi’s years at UC Berkeley October 24, 2022
    • Technion #1 in Europe in Field of AI for 2nd Straight Year October 20, 2022
    • Endoglin Protein Interactome Profiling Identifies TRIM21 and Galectin-3 as New Binding Partners October 11, 2022
    • The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells October 11, 2022
    • Cancer Policy Related News from Washington DC and New NCI Appointments October 4, 2022
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 Amandeep Kaur
    • 1 Aashir Awan, Phd
    • 1 Abhisar Anand
    • 1 Adina Hazan
    • 1 Alan F. Kaul, PharmD., MS, MBA, FCCP
    • 1 alexcrystal6
    • 1 anamikasarkar
    • 1 apreconasia
    • 1 aviralvatsa
    • 1 David Orchard-Webb, PhD
    • 1 danutdaagmailcom
    • 1 Demet Sag, Ph.D., CRA, GCP
    • 1 Dror Nir
    • 1 dsmolyar
    • 1 Ethan Coomber
    • 1 evelinacohn
    • 1 Gail S Thornton
    • 1 Irina Robu
    • 1 jayzmit48
    • 1 jdpmd
    • 1 jshertok
    • 1 kellyperlman
    • 1 Ed Kislauskis
    • 1 larryhbern
    • 1 Madison Davis
    • 1 marzankhan
    • 1 megbaker58
    • 1 ofermar2020
    • 1 Dr. Pati
    • 1 pkandala
    • 1 ritusaxena
    • 1 Rick Mandahl
    • 1 sjwilliamspa
    • 1 Srinivas Sriram
    • 1 stuartlpbi
    • 1 Dr. Sudipta Saha
    • 1 tildabarliya
    • 1 vaishnavee24
    • 1 zraviv06
    • 1 zs22

Powered by WordPress.com.

WPThemes.


 

Loading Comments...
 

    %d bloggers like this: